New Ray Medicine International Holding Limited (HKG:6108)
Hong Kong · Delayed Price · Currency is HKD 0.2350
-0.0140 (-5.62%)
At close: Jan 28, 2026
HKG:6108 Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 121.93 | 93.95 | 50.15 | 89.77 | 335.38 | 133.21 | Upgrade | |
Revenue Growth (YoY) | 240.05% | 87.31% | -44.13% | -73.23% | 151.76% | 12.29% | Upgrade |
Cost of Revenue | 126.14 | 95.57 | 38.81 | 118.96 | 306.89 | 122.28 | Upgrade |
Gross Profit | -4.21 | -1.62 | 11.34 | -29.18 | 28.49 | 10.93 | Upgrade |
Selling, General & Admin | 30.84 | 30.6 | 28.7 | 39.61 | 30.92 | 27.95 | Upgrade |
Operating Expenses | 36.52 | 36.31 | 32.76 | 44.23 | 35.57 | 55.82 | Upgrade |
Operating Income | -40.73 | -37.94 | -21.42 | -73.42 | -7.08 | -44.89 | Upgrade |
Interest Expense | -0.18 | -0.1 | -0.03 | -0.18 | -0.28 | -0.11 | Upgrade |
Interest & Investment Income | 1.19 | 2.53 | 3.68 | 3.37 | 1.3 | 1.76 | Upgrade |
Earnings From Equity Investments | - | - | - | - | 1.11 | 1.48 | Upgrade |
Currency Exchange Gain (Loss) | -0.59 | -0.67 | -0.57 | -10.63 | 4.25 | 8.92 | Upgrade |
Other Non Operating Income (Expenses) | 0.01 | 0.05 | -2.11 | 0.07 | 0.09 | 0.1 | Upgrade |
EBT Excluding Unusual Items | -40.3 | -36.13 | -20.45 | -80.79 | -0.62 | -32.73 | Upgrade |
Gain (Loss) on Sale of Investments | 4.87 | 3.93 | 0.42 | - | -2.99 | -37.33 | Upgrade |
Gain (Loss) on Sale of Assets | -0 | 0.14 | 0.48 | 0.38 | -0.01 | -0.01 | Upgrade |
Asset Writedown | - | - | -2.8 | - | - | - | Upgrade |
Other Unusual Items | - | - | - | 0.12 | - | 0.16 | Upgrade |
Pretax Income | -35.43 | -32.06 | -22.34 | -80.29 | -3.61 | -69.9 | Upgrade |
Income Tax Expense | -1.05 | -1.05 | -0.17 | -2.34 | -0.78 | -0.17 | Upgrade |
Net Income | -34.38 | -31.01 | -22.17 | -77.95 | -2.82 | -69.73 | Upgrade |
Net Income to Common | -34.38 | -31.01 | -22.17 | -77.95 | -2.82 | -69.73 | Upgrade |
Shares Outstanding (Basic) | 167 | 167 | 167 | 167 | 167 | 167 | Upgrade |
Shares Outstanding (Diluted) | 167 | 167 | 167 | 167 | 167 | 167 | Upgrade |
Shares Change (YoY) | -81.82% | - | - | - | - | - | Upgrade |
EPS (Basic) | -0.21 | -0.19 | -0.13 | -0.47 | -0.02 | -0.42 | Upgrade |
EPS (Diluted) | -0.21 | -0.19 | -0.13 | -0.47 | -0.02 | -0.42 | Upgrade |
Free Cash Flow | -22.03 | -5.39 | -45.45 | -9.02 | -58.45 | -31.84 | Upgrade |
Free Cash Flow Per Share | -0.13 | -0.03 | -0.27 | -0.05 | -0.35 | -0.19 | Upgrade |
Gross Margin | -3.45% | -1.73% | 22.61% | -32.51% | 8.49% | 8.21% | Upgrade |
Operating Margin | -33.41% | -40.38% | -42.71% | -81.78% | -2.11% | -33.70% | Upgrade |
Profit Margin | -28.20% | -33.01% | -44.20% | -86.83% | -0.84% | -52.34% | Upgrade |
Free Cash Flow Margin | -18.07% | -5.73% | -90.62% | -10.04% | -17.43% | -23.90% | Upgrade |
EBITDA | -38.86 | -36.23 | -16.63 | -68.46 | -2.86 | -40.76 | Upgrade |
EBITDA Margin | -31.87% | -38.57% | -33.15% | -76.27% | -0.85% | -30.59% | Upgrade |
D&A For EBITDA | 1.87 | 1.7 | 4.8 | 4.95 | 4.22 | 4.13 | Upgrade |
EBIT | -40.73 | -37.94 | -21.42 | -73.42 | -7.08 | -44.89 | Upgrade |
EBIT Margin | -33.41% | -40.38% | -42.71% | -81.78% | -2.11% | -33.70% | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.